Limited-stage small cell lung cancerRadical surgeryNeoadjuvant chemotherapyConcurrent chemoradiotherapyPrognosisThe screening process for patients in this studydoi:10.1186/s12957-020-1807-1Lili ZhongJiaojiao SuoYa WangJialong HanJiang ZhuWorld Journal of Surgical Oncology...
(durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent ...
Aim:To compare the effects of single chemotherapy( CRT) and conformal radiotherapy combined with chemotherapy( CCRT) on limited disease small cell lung cancer( LD-SCLC) patients after balancing the covariates by propensity score. Methods:A total of 224 LD-SCLC patients were subjected,among which,...
According to GLOBOCAN 2020, lung cancer is a form of malignant tumor with the highest incidence rate and mortality in China. Lung cancer can be broadly categorized into non-small cell lung cancer (“NSCLC”) and small cell...
We propose two biologically interpretable and robust deep-learning architectures for survival prediction of 130 non-small cell lung cancer (NSCLC) patients, integrating patient-specific clinical, transcriptomic, and imaging data. We incorporate KEGG and Reactome pathway information, adding biological ...
To improve the prognosis of limited stage small cell lung cancer (LS-SCLC) the addition of concurrent thoracic radiotherapy to a platinum-containing regimen is important. In the Netherlands, we initiated a multicenter, phase II study, of the combination of four cycles of carboplatin (AUC 5), ...
From 1975 through 1990, 199 patients with limited small cell lung cancer (LSCLC) were subjected to multimodality treatment including surgical resection combined with chemotherapy or chemoradiotherapy in our department. The median postoperative survival time of the 199 patients was 39 months, and the 5...
Gastrointestinal symptoms are common in COVID-19 patients but the nature of the gut immune response to SARS-CoV-2 remains poorly characterized, partly due to the difficulty of obtaining biopsy specimens from infected individuals. In lieu of tissue sample
The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progressio...
The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progressio...